Atossa Therapeutics (ATOS) Other Accumulated Expenses (2012 - 2026)

Atossa Therapeutics (ATOS) has reported Other Accumulated Expenses for 15 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 25.62% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 25.62% YoY), while the FY2025 annual figure was $1.1 million, down 26.67% from the prior year.
• Other Accumulated Expenses advanced to $1.1 million in Q1 2026 per ATOS's latest filing, from $1.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.8 million in Q4 2023 and bottomed at $13000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $911823.5 across 5 years, with a median of $1.1 million in 2026.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 9373.68% — and 2025, when it dropped 26.67%.
• Atossa Therapeutics' Other Accumulated Expenses stood at $19000.0 in 2022, then surged by 9373.68% to $1.8 million in 2023, then fell by 16.67% to $1.5 million in 2024, then fell by 26.67% to $1.1 million in 2025, then increased by 3.45% to $1.1 million in 2026.
• Business Quant data shows ATOS's Other Accumulated Expenses at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.6 million in Q3 2025.